ReviewCell and tissue research2018
Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.
Review in Cell and tissue research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Review
- Pheochromocytomas and Paragangliomas.Endocrinology and metabolism clinics of North America · 2026Review
- Adrenal causes of endocrine hypertension in childhood or adolescence.Journal of endocrinological investigation · 2025Review
- The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.Endocrine reviews · 2024Review
- Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas.Cancers · 2023Review
- Article
- Article
- Review
- Frequently asked questions and answers (if any) in patients with adrenal incidentaloma.Journal of endocrinological investigation · 2021Review
- Precision Medicine in Phaeochromocytoma and Paraganglioma.Journal of personalized medicine · 2021Review
- From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas.Current urology reports · 2021Review
- Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.Frontiers in endocrinology · 2021Review
- Haemorrhagic retroperitoneal paraganglioma initially manifesting as acute abdomen: a rare case report and literature review.BMC surgery · 2020Review
- Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine.Human molecular genetics · 2020Review
- Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management.Pediatric nephrology (Berlin, Germany) · 2020Review
- Progress in the diagnosis and treatment of paraganglioma.Translational cancer research · 2019Review
- Novel PET tracers: added value for endocrine disorders.Endocrine · 2019Review
- The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?Theranostics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Pheochromocytomas and their extra-adrenal counterpart paragangliomas (PGLs; together called PPGLs), belong to the family of neural crest-derived tumors. Given the overexpression of a wide variety of specific targets in PPGLs, it seems that these tumors are optimally suited to be imaged by specific radiopharmaceuticals. Thus, theranostics approaches with somatostatin agonists and antagonists are rapidly evolving in the setting of these tumors and may be considered as the next step in the therapeutic arsenal of metastatic PPGLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.